3093 completed. 3093 Phase 1, 811 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3093 | Completed 3093 |
| Phase 2 | 811 | Completed 811 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Pharmacokinetics and Safety of Miricorilant Miricorilant - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | Phase 1 | Completed | Corcept Therapeutics | 14 | 2026-04-30 | 2026-10-16 |
| Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls Hydronidone capsules - Liver Fibrosis | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 30 | 2026-03-25 | 2026-08-13 |
| Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function Pevifoscorvir Sodium (ALG-000184) - Chronic Hepatitis B Infection | Phase 1 | Completed | Aligos Therapeutics | 12 | 2026-03-10 | 2026-08-21 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry Efimosfermin alfa, Placebo - Non-alcoholic Fatty Liver Disease | Phase 1 | Completed | GlaxoSmithKline | 30 | 2026-03-05 | 2026-09-21 |
| Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants VNZ/TEZ/D-IVA, Rosuvastatin - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 18 | 2026-01-12 | 2026-04-02 |
| QTc Assessment in a Single-Dose Study of Hydronidone Capsules Hydronidone, Placebo - Hepatic Fibrosis | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 48 | 2025-12-30 | 2026-08-13 |
| The Phase Ⅰd Clinical Trial of Hydronidone Capsules Hydronidone capsules, Placebo capsules - Liver Fibrosis | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 138 | 2025-12-24 | 2026-09-21 |
| Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants ALTB-268, Placebo - Ulcerative Colitis (UC) | Phase 1 | Completed | AltruBio Inc. | 24 | 2025-11-17 | 2026-10-29 |
| A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin Drug Drug Interaction - Drug Interaction, GERD (Gastroesophageal Reflux Disease) | Phase 1 | Completed | Cinclus Pharma Holding AB | 12 | 2025-11-11 | 2026-02-27 |
| A Clinical Study to Evaluate SM17 in Healthy Participants SM17, SM17 placebo - Atopic Dermatitis, Asthma | Phase 1 | Completed | SinoMab BioScience Ltd | 30 | 2025-10-14 | 2026-04-06 |
| A Phase I Study of INT-210 Capsules in Healthy Adult Subjects (INT-210-I101) INT-210 Capsule, INT-210 Placebo - IBD (Inflammatory Bowel Disease) | Phase 1 | Completed | Innatus Therapeutics (Shanghai) Co., Ltd. | 86 | 2025-09-04 | 2026-06-01 |
| A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease HB-2121 - Celiac Disease, Healthy | Phase 1 | Completed | Nielsen Fernandez-Becker | 18 | 2025-08-26 | 2026-07-28 |
| Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers Single Dose G1090N, Multiple dosing of G1090N - Acute-on-Chronic Liver Failure | Phase 1 | Completed | Genfit | 52 | 2025-08-26 | 2026-01-16 |
| Evaluation of Miricorilant on Liver Fat in Patients With MASLD Miricorilant - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1 | Completed | Corcept Therapeutics | 9 | 2025-08-22 | 2026-09-30 |
| A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) Bomedemstat - Hepatic Insufficiency | Phase 1 | Completed | Merck Sharp & Dohme LLC | 9 | 2025-08-20 | 2026-02-25 |
| A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems BI 1584862 - Hepatic Insufficiency | Phase 1 | Completed | Boehringer Ingelheim | 43 | 2025-08-06 | 2026-07-07 |
| A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose Sevabertinib - Hepatic Insufficiency, Liver Diseases | Phase 1 | Completed | Bayer | 18 | 2025-07-24 | 2026-02-10 |
| Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants. SION-451, SION-2222, SION-109 - Cystic Fibrosis (CF) | Phase 1 | Completed | Sionna Therapeutics Inc. | 120 | 2025-07-23 | 2026-09-10 |
| Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule - Eosinophilic Esophagitis | Phase 1 | Completed | AQILION AB | 9 | 2025-06-13 | 2026-06-01 |
| A Study of Varenicline in the Treatment of Visceral Sensation Varenicline - Irritable Bowel Syndrome | Phase 1 | Completed | Mayo Clinic | 8 | 2025-06-01 | 2026-01-06 |
Showing 20 of 3093. Sign in to see all of them.
Colorectal Neoplasms (515) · Pancreatic Neoplasms (468) · Stomach Neoplasms (246) · Colonic Neoplasms (241) · Hepatitis C (235) · Carcinoma, Hepatocellular (231) · Breast Neoplasms (205) · Carcinoma, Non-Small-Cell Lung (198) · Neoplasms (195) · Rectal Neoplasms (183) · Ovarian Neoplasms (174) · Esophageal Neoplasms (165) · Cystic Fibrosis (153) · Liver Neoplasms (141) · Neoplasm Metastasis (132)
Neoplasms by Site (1557) · Digestive System Neoplasms (1552) · Gastrointestinal Diseases (1465) · Neoplasms (1416) · Liver Diseases (1044) · Intestinal Diseases (1035) · Gastrointestinal Neoplasms (924) · Colonic Diseases (761) · Intestinal Neoplasms (680) · Pancreatic Diseases (663) · Pathological Conditions, Signs and Symptoms (661) · Rectal Diseases (647) · Endocrine System Diseases (624) · Neoplasms by Histologic Type (606)
Gemcitabine (172) · Oxaliplatin (126) · Fluorouracil (119) · Capecitabine (114) · Irinotecan (100) · Leucovorin (86) · Cisplatin (77) · Bevacizumab (65) · Radiotherapy (65) · Nivolumab (63) · Sorafenib (62) · pembrolizumab (62) · Cetuximab (59) · 130-nm albumin-bound paclitaxel (56) · Albumin-Bound Paclitaxel (51)
National Cancer Institute (NCI) (106) · GlaxoSmithKline (57) · Bristol-Myers Squibb (56) · Merck Sharp & Dohme LLC (54) · AstraZeneca (49) · Pfizer (49) · Boehringer Ingelheim (40) · Gilead Sciences (38) · Novartis Pharmaceuticals (37) · Eli Lilly and Company (36) · M.D. Anderson Cancer Center (36) · Mayo Clinic (35) · Memorial Sloan Kettering Cancer Center (34) · Vertex Pharmaceuticals Incorporated (34) · Hoffmann-La Roche (30)
United States (1699) · United Kingdom (232) · China (226) · South Korea (188) · Germany (172) · Canada (162) · Spain (150) · France (147) · Australia (134) · Belgium (124) · Japan (118) · Netherlands (107) · Taiwan (84) · Italy (83) · New Zealand (64)
PMID 33331662, PMID 37983082, PMID 22473314, PMID 31215818, PMID 39863139, PMID 18590344, PMID 18590345, PMID 19192962, PMID 19949018, PMID 21488067, PMID 22002018, PMID 22607579, PMID 27009167, PMID 27257978, PMID 27490698, PMID 28735965, PMID 29703432, PMID 30277655, PMID 30625297, PMID 32671834, PMID 32939319, PMID 33317695, PMID 34017343, PMID 34256305, PMID 35227647, PMID 35771259, PMID 36897458, PMID 36977960, PMID 37082579, PMID 37319354, PMID 37496366, PMID 37917289, PMID 38267790, PMID 39363243, PMID 39462179, PMID 39798707, PMID 41044356, PMID 42550463, PMID 10235156, PMID 10496568, PMID 10628373, PMID 10655252, PMID 10811496, PMID 11127145, PMID 11573045, PMID 11705489, PMID 11743810, PMID 11870157, PMID 11919232, PMID 11919233
2016 (39), 2015 (26), 2017 (23), 2018 (21), 2009 (17), 2014 (17), 2019 (15), 2008 (14), P30CA016672 (11), 2023 (6), P30CA012197 (6), P30CA015083 (6), U01CA069856 (6), U01CA132123 (6), P30CA016056 (5)